1.
Int Forum Allergy Rhinol
; 14(1): 123-126, 2024 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37394843
RESUMO
KEYPOINTS: Between 2007 and 2022, the FDA received 119 US-based reports mentioning budesonide nasal irrigation. Most reports were submitted by patients and alerted FDA to off-label usage of budesonide. Notable adverse events reported to the FDA included headache, dyspnea, and blurred vision.